Just been diving into Cardinal Health's latest moves and honestly, this health care stock is looking pretty compelling right now. The company's clearly executing well on its specialty pivot, and there's some real momentum building across multiple business lines.

Let me break down what caught my attention. In fiscal Q2, Cardinal Health crushed it with pharmaceutical distribution revenue jumping 19% to $61 billion, while segment profit surged 29%. But here's the thing that really matters - they're not just growing the traditional pharma distribution business. Specialty revenues are expected to hit $50 billion this year, which is a huge shift toward higher-margin therapies like oncology and urology. That's the kind of structural change that compounds over time.

What's even more interesting is their other growth businesses. Nuclear and Precision Health Solutions, at-home care, and logistics delivered 34% revenue growth with 52% profit growth in the quarter. Theranostics alone grew over 30% with more than 70 products in their pipeline. This is the real earnings diversification story - they're not betting everything on thin-margin pharmaceutical distribution anymore.

The medical segment turnaround is worth watching too. GMPD profit more than doubled year-over-year from $18 million to $37 million, driven by restructuring and stronger demand for their branded products. If this momentum holds, it could shift from being a drag on earnings to actually contributing meaningfully to profitability.

Now, there are some headwinds to consider. Management's flagging that profit growth in pharma will moderate to mid-teens in the second half, mainly because they're comparing against $10 billion in new customer onboarding from last year. That's just tough comparisons, not necessarily weakness. Tariffs are also pressuring the medical segment margins, though cost optimization has helped offset some of that impact. And yeah, core pharmaceutical distribution still operates on razor-thin margins - GLP-1 therapies are driving volume but not much profit.

The numbers support the thesis though. Earnings estimates have been revised up 2.7% over the past month to $10.31 per share for fiscal 2026. Consensus is calling for Q3 revenues around $62.42 billion, up 13.7% year-over-year, with EPS expected at $2.80, representing 19.2% growth. The stock's already up 49% in six months versus 23% for the industry, but given what they're building with specialty services and adjacent businesses, there's still room to run.

This health care stock has the scale, the margin expansion story, and the earnings beat track record - they've beaten expectations four quarters running with an average 9.3% surprise. If you're looking for exposure to healthcare services with real structural tailwinds, Cardinal Health deserves a closer look.